Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Chelerythrine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCHE known ✓ | P06276 | 5/20 | 0.98 |
| ▸ | ACHE known ✓ | P22303 | 5/20 | 0.98 |
| ▸ | MAOA known ✓ | P21397 | 1/20 | 0.98 |
| ▸ | PPARG known ✓ | P37231 | 1/20 | 0.98 |
| ▸ | PRKCE known ✓ | Q02156 | 1/20 | 0.95 |
| ▸ | CHRM1 known ✓ | P11229 | 2/20 | 0.48 |
| ▸ | DRD2 known ✓ | P14416 | 2/20 | 0.48 |
| ▸ | ADRA2B known ✓ | P18089 | 2/20 | 0.48 |
| ▸ | ADRA2C known ✓ | P18825 | 2/20 | 0.48 |
| ▸ | DRD1 known ✓ | P21728 | 2/20 | 0.48 |
| ▸ | HTR2B known ✓ | P41595 | 2/20 | 0.48 |
| ▸ | KCNH2 known ✓ | Q12809 | 2/20 | 0.48 |
| ▸ | SIGMAR1 known ✓ | Q99720 | 2/20 | 0.48 |
| ▸ | DPP4 known ✓ | P27487 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.98 |
| ▸ | MAPT | P10636 | 7/20 | 0.98 |
| ▸ | SMN1; SMN2 | Q16637 | 7/20 | 0.98 |
| ▸ | HPGD | P15428 | 5/20 | 0.98 |
| ▸ | MAPK1 | P28482 | 5/20 | 0.98 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.98 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Chelerythrine SCHEMBL4016265 | 1.00 | ALDH1A1 (0.98) | ALDH1A1MAPTSMN1; SMN2HPGDMAPK1 | |
| Chelerythrine SCHEMBL30527168 | 0.99 | ALDH1A1 (1.00) | ALDH1A1MAPTSMN1; SMN2HPGDMAPK1 | |
| Chelerythrine SCHEMBL30527167 | 0.99 | ALDH1A1 (1.00) | ALDH1A1MAPTSMN1; SMN2HPGDMAPK1 | |
| Chelerythrine SCHEMBL29357531 | 0.99 | ALDH1A1 (1.00) | ALDH1A1MAPTSMN1; SMN2HPGDMAPK1 | |
| Chelerythrine SCHEMBL288915 | 0.99 | ALDH1A1 (1.00) | ALDH1A1MAPTSMN1; SMN2HPGDMAPK1 | |
| Chelerythrine SCHEMBL3319851 | 0.98 | ALDH1A1 (0.98) | ALDH1A1MAPTSMN1; SMN2HPGDMAPK1 | |
| Chelerythrine SCHEMBL288916 | 0.98 | ALDH1A1 (0.98) | ALDH1A1MAPTSMN1; SMN2HPGDMAPK1 | |
| Chelerythrine SCHEMBL195109 | 0.98 | ALDH1A1 (1.00) | ALDH1A1MAPTSMN1; SMN2HPGDMAPK1 | |
| Chelerythrine SCHEMBL30207103 | 0.98 | ALDH1A1 (1.00) | ALDH1A1MAPTSMN1; SMN2HPGDMAPK1 | |
| Chelerythrine SCHEMBL3973425 | 0.94 | ALDH1A1 (0.91) | ALDH1A1MAPTSMN1; SMN2HPGDMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117064890-A | Application of chelerythrine hydrochloride in preparing medicament for treating psoriasis | 贵州省天然产物研究中心 | 2023-11-17 | — | — | CN | claimed |
| CN-110679612-A | Agricultural insecticidal composition for preventing and treating corn borers | 宁波市鄞州赛弗兑食品科技有限公司 | 2020-01-14 | — | — | CN | claimed |
| CN-101775022-A | Ion-pair compound of chelerythrine from Chinese medicine extracts, preparation and application thereof | JIANGUO ZENG | 2010-07-14 | — | — | CN | claimed |
| CN-118638126-A | Tritiated sanguinarine and preparation method and application thereof | 湖南农业大学 | 2024-09-13 | — | — | CN | disclosed |
| CN-117121918-A | Application of sanguinarine and analogues thereof | 贵州大学 | 2023-11-28 | — | — | CN | disclosed |
| CN-117064890-A | Application of chelerythrine hydrochloride in preparing medicament for treating psoriasis | 贵州省天然产物研究中心 | 2023-11-17 | — | — | CN | disclosed |
| CN-117064890-A | Application of chelerythrine hydrochloride in preparing medicament for treating psoriasis | 贵州省天然产物研究中心 | 2023-11-17 | — | — | CN | disclosed |
| CN-117064890-A | Application of chelerythrine hydrochloride in preparing medicament for treating psoriasis | 贵州省天然产物研究中心 | 2023-11-17 | — | — | CN | disclosed |
| CN-114456144-B | Intermediate compound for preparing sanguinarine by chemical synthesis and preparation method thereof | 宁波九胜创新医药科技有限公司 | 2023-10-13 | — | — | CN | disclosed |
| CN-114456185-B | Chemical synthesis method of sanguinarine | 宁波九胜创新医药科技有限公司 | 2023-09-01 | — | — | CN | disclosed |
| CN-113816967-B | Method, composition and application of bio-orthogonal photocatalytic oxidative dehydrogenation activated antitumor compound | 华南理工大学 | 2023-04-21 | — | — | CN | disclosed |
| CN-101824061-B | Baicalin ion pair medicine from traditional Chinese medicine of baikal skullcap root as well as preparation method and application thereof | ZENG JIANGUO (CN) | 2012-02-15 | — | — | CN | disclosed |
| CN-101195627-B | New application of benzo [C] phenanthridine and protopine in producing overriding resistant bacterium medicament | KUNMING GENERAL HOSPITAL CHENGDU MILITARY AREA | 2010-11-24 | — | — | CN | disclosed |
| CN-101824061-A | Baicalin ion pair medicine from traditional Chinese medicine of baikal skullcap root as well as preparation method and application thereof | JIANGUO ZENG | 2010-09-08 | — | — | CN | disclosed |
| CN-101775022-A | Ion-pair compound of chelerythrine from Chinese medicine extracts, preparation and application thereof | JIANGUO ZENG | 2010-07-14 | — | — | CN | disclosed |
| CN-101195627-A | New application of benzo [C] phenanthridine and protopine in producing overriding resistant bacterium medicament | KUNMING GENERAL HOSPITAL CHENG (CN) | 2008-06-11 | — | — | CN | disclosed |
| CN-100387602-C | Chelerythrine compound and its preparing method | QINGHONG ZHANG (CN) | 2008-05-14 | — | — | CN | disclosed |
| US-20080076781-A1 | PSEUDOBASE BENZO[C]PHENANTHRIDINES WITH IMPROVED EFFICACY, STABILITY, AND SAFETY | MARINUS PHARMACEUTICALS INC. (US) | 2008-03-27 | — | — | US | disclosed |
| CN-1891703-A | Chelerythrine compound and its preparing method | ZHANG QINGHONG (CN) | 2007-01-10 | — | — | CN | disclosed |
| CN-1532197-A | Process for separating and preparing hig purity samguinarine and chelerythrine | 湖南师范大学 | 2004-09-29 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080076781-A1 | PSEUDOBASE BENZO[C]PHENANTHRIDINES WITH IMPROVED EFFICACY, STABILITY, AND SAFETY | TOP1, TOP2B, TOP2A | BCHE 1477/4885ACHE 2721/4885MAOA 2631/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.